NX Prenatal Inc. is a private US based molecular diagnostics company with locations in Louisville, KY and Houston, TX. NX Prenatal is developing diagnostic assays for adverse pregnancy conditions such as preterm birth. It employs the proprietary NeXosome® platform, which enables advanced isolation and enrichment of exosome and microvesicle particles from bodily fluids for non-invasive biomarker evaluation. We are planning the US launch of the NeXosome Preterm Birth Risk Assay, which detects a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation. This technology may provide physicians an ideal opportunity to intervene in a timely manner with protocols for at-risk pregnancies in an attempt to reduce the likelihood of a preterm birth or minimize the complications that can arise for both the child and the mother.
Gail S. Page
Executive Chairperson, Co-CEO
Gail is a veteran women’s health diagnostics executive. In January 2013 Ms. Page founded Vineyard Investment Advisors to partner with entrepreneurs, businesses, and universities to transform their ideas into products and services. Prior to this, Gail served as the President, CEO and Director of Vermillion, Inc. from 2006 thru December 2012. Under her leadership, Vermillion developed and commercially launched the first FDA-cleared blood test to help diagnose ovarian cancer. Prior to this, Gail held executive leadership positions at Luminex, LabCorp, and Roche Biomedical.
Brian D. Brohman
Co-founder, Director, Co-CEO
Brian was the previous founding CFO/CBO of biotech startups Aptamera (sold to Antisoma), Bradmer Pharmaceuticals (IPO’d on TSX), and NX PharmaGen (affiliate of NX Prenatal). Prior to these roles, Mr. Brohman served as a licensing/business development professional at J&J’s Cordis medical devices division, and is a graduate of the University of Notre Dame’s Mendoza College of Business.
Kevin Rosenblatt, MD, PhD
Chief Medical & Scientific Officer
Dr. Rosenblatt previously served as CSO/CMO of CompanionDx Labs, a precision medicine company focused on diagnostics. With 26 years of experience as a renowned molecular pathologist and industry veteran, Dr. Rosenblatt is recognized internationally for proteomics and genomics with an emphasis in oncology, drug metabolism and neurode-generative diseases. He also previously served as CEO of Risk Assessment Laboratories, which focused on preterm birth biomarkers in conjunction with Perkin-Elmer.
Advisory Team Members
Robert C. Doss, Ph.D., VP Product Development, is a Senior Executive with more than 25 years of Leadership experience in the Global Diagnostics and related Health Care fields. He has an exemplary record in delivering over 80 new products to market within a $3B business unit of Abbott Diagnostics. He held senior management positions in domestic and international R&D, Quality Assurance, Regulatory Affairs and Technical Product Support. Dr. Doss has proven experience in organizational assessment, organizational design, talent management and talent acquisition, and has earned a reputation as results-oriented, practical, analytical, innovative and collaborative.
C. David Adair, MD, MBA, Director, is the Co-Founder and Managing Director of Solas Bioventures. Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care, Dr. Adair is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. He recently retired from his position as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine, and also retired from clinical practice after a 30 year career.
Mary Lake Polan, MD, PhD, MPH, Member of Medical/Clinical Advisory Board, and Director. Dr. Polan is a Clinical Professor in the Department of Obstetrics and Gynecology and Reproductive Sciences Yale University School of Medicine; she is also Chair Emeritus of the Department of Obstetrics and Gynecology at Stanford University. She has published more than 130 articles, chapters, and books in her areas of research, which include reproductive endocrinology and infertility. She is a member of the National Academy of Medicine and has served on a number of NIH and university committees.
Daniel W. Chan, PhD, DABCC, FACB, Member of Medical/Clinical Advisory Board. Dr. Chan is Professor of Pathology, Oncology, Radiology, and Urology at the Johns Hopkins University School of Medicine, and Director of the Clinical Chemistry Division and Co-Director of the Pathology Core Laboratory of Johns Hopkins Hospital in Baltimore. Dr. Chan is also Director of the Biomarker Discovery and Translation Center, Johns Hopkins University. Dr. Chan received his BA degree in Biology from the University of Oregon and his Ph.D. in Biochemistry from the State University of New York at Buffalo. He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics. He has written 5 books, 40 book chapters and 300 scientific articles. He is the Editor-in-Chief of the journal Clinical Proteomics.
Thomas McElrath, MD, PhD, FACOG, Member of Medical/Clinical Advisory Board. Dr. McElrath is Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and an attending physician at Brigham & Women's Hospital where he specializes in Maternal & Fetal Medicine with a focus on the prevention of spontaneous preterm birth. Dr. McElrath manages the Preterm Birth Clinic at Brigham and Women’s Hospital. He actively publishes on the biomarker epidemiology and classification of preterm birth and the interaction of environmental conditions and exposures with the risk of preterm birth.
Zhen Zhang, Ph.D., Scientific Advisor, is an expert in bioinformatics and statistics, and is the associate director of the Center for Biomarker Discovery and Translation at John Hopkins University School of Medicine. Dr. Zhang has conducted biomarker research for over 20 years, in particular in the design of biomarker discovery and validation studies, and the development of in vitro diagnostic multivariate index assays (IVDMIA) for clinical applications. He was an integral part of the discovery and development of the OVA1 test for pre-surgery assessment of malignancy risk for women diagnosed with a pelvic mass. OVA1 was the first ever IVDMIA protein marker test cleared by FDA for clinical use.
Alan Mack, Director, is a successful entrepreneur and executive in the diagnostics field, and is the Founder, President and CEO of NxGEN MDx LLC, a leading clinical molecular diagnostics laboratory providing best-in-class genetic carrier screening tests as trusted tools for early family planning. He previously held executive leadership positions at Arctic Medical Laboratories, Asendant MDx, and the Sequenom Center for Molecular Medicine. Earlier in his career, Mr. Mack held diagnostics sales leadership positions at firms including TM Bioscience and Quest Diagnostics.
Robert S. Saunders, Director, is a General Partner of OCA Ventures (Chicago), a Founding Partner of Saunders Murdock and Associates (Louisville/Boston), and is an active investor in many healthcare startups. Mr. Saunders was a Managing Director and General Partner at Chrysalis Ventures from 1997 to 2009. Over the last 30 years, he has invested in several dozen startup companies and has mentored 100+ startups. He received a B.A. from Stanford University, an M.Sc. from the London School of Economics, and an M.A. from Harvard University. He was both a Fulbright Scholar and a Marshall Scholar.